

Date: February 13, 2025

| | |
|--|--|
| To, The Manager, Listing Department, National Stock Exchange of India Limited (NSE), Exchange Plaza, C - 1, Block - G, Bandra - Kurla Complex, Bandra (E), Mumbai-400 051. | To, The Department of Corporate Service, BSE Limited, 1 st Floor, New Trading Ring, Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai - 400 001. |
| Symbol - LINCOLN | Scrip Code - 531633 |

Dear Sir,

Sub:- Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2024.

Pursuant to Regulation 33 of the Securities and Exchange Board of India Pursuant to Regulation 10(1A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD-PoD2/CIR/P/2024/185 dated 31st December, 2024, BSE Circular No. 20250102-4 dated 02nd January, 2025 and NSE Circular No. NSE/CMLI2025/02 dated 02nd January, 2025, please find enclosed herewith the Integrated Filing (Financial) for the quarter and nine months ended 31st December, 2024.

The aforesaid documents are being placed on the website of the Company i.e. www.lincolnpharma.com.

Kindly take the same on your records.

Thanking you,

Yours faithfully,
For Lincoln Pharmaceuticals Limited

Trusha Shah
Company Secretary &
Compliance Officer

Encl: A/a

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2024.

| Sr. No. | Particulars | ₹ in Lakhs Except Earnings Per Share Data | | | | | |
|---------|--|---|----------------------------|----------------------------|----------------------------|----------------------------|-------------------------|
| | | Quarter Ended | | | Nine Months Ended | | Year Ended |
| | | 31/12/2024 (Un-Audited) | 30/09/2024 (Un-Audited) | 31/12/2023 (Un-Audited) | 31/12/2024 (Un-Audited) | 31/12/2023 (Un-Audited) | 31/03/2024 (Audited) |
| 1 | Income | | | | | | |
| | A) Revenue From Operations | 14,655.17 | 16,121.35 | 14,644.93 | 45,504.70 | 43,805.66 | 58,054.96 |
| | B) Other Income | 897.00 | 997.76 | 1,101.79 | 2,935.68 | 2,740.34 | 3,442.25 |
| | Total Income (1) | 15,552.17 | 17,119.11 | 15,746.72 | 48,440.38 | 46,546.00 | 61,497.21 |
| 2 | Expenses | | | | | | |
| | A) Cost of Material Consumed | 5,015.90 | 5,710.33 | 5,687.75 | 16,000.79 | 14,923.73 | 20,112.45 |
| | B) Purchase of Stock-In-Trade | 1,860.91 | 2,185.50 | 3,051.04 | 5,379.48 | 6,591.31 | 8,291.48 |
| | C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP | (13.25) | (666.49) | (2,029.79) | (263.51) | (1,038.89) | (570.06) |
| | D) Employee Benefits Expenses | 2,797.78 | 2,783.62 | 2,643.68 | 8,483.39 | 7,784.70 | 10,289.96 |
| | E) Finance Costs | 72.81 | 34.88 | 15.47 | 151.60 | 96.35 | 146.26 |
| | F) Deprecation and Amortisation Expense | 322.43 | 322.44 | 281.38 | 967.30 | 793.89 | 1,062.47 |
| | G) Other Expenses | 2,627.49 | 3,270.51 | 2,326.16 | 8,427.12 | 7,392.37 | 9,940.39 |
| | Total Expenses (2) | 12,684.07 | 13,640.79 | 11,975.69 | 39,146.17 | 36,543.46 | 49,272.95 |
| 3 | Profit / (Loss) Before Exceptional Items & Tax (1-2) | 2,868.10 | 3,478.32 | 3,771.03 | 9,294.21 | 10,002.54 | 12,224.26 |
| 4 | Exceptional Items | Nil | Nil | Nil | Nil | Nil | Nil |
| 5 | Profit / (Loss) after Exceptional items but Before Tax (3-4) | 2,868.10 | 3,478.32 | 3,771.03 | 9,294.21 | 10,002.54 | 12,224.26 |
| 6 | Tax Expense | | | | | | |
| | A) Current Tax | 754.90 | 511.80 | 721.00 | 1,818.00 | 2,133.00 | 2,520.50 |
| | B) Deferred Tax | (13.34) | 333.49 | 246.01 | 349.47 | 398.76 | 349.48 |
| | C) Short / (Excess) Tax Provision | 49.60 | Nil | Nil | 49.60 | Nil | 23.79 |
| 7 | Net Profit / (Loss) For The Period (5-6) | 2,076.94 | 2,633.03 | 2,804.02 | 7,077.14 | 7,470.78 | 9,330.49 |
| 8 | Other Comprehensive Income (Net Of Tax) Items that will not be reclassified to subsequently to profit and loss | 1.52 | 1.53 | (7.44) | 4.58 | (22.33) | 6.11 |
| | Items that will be reclassified subsequently to profit or loss | Nil | Nil | Nil | Nil | Nil | Nil |
| 9 | Total Comprehensive Income | 2,078.46 | 2,634.56 | 2,796.58 | 7,081.72 | 7,448.45 | 9,336.60 |
| 10 | Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each) | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 |
| 11 | Other Equity | | | | | | 57,280.62 |
| 12 | Earnings Per Share (of Rs. 10/- Each) (Not Annualised) | | | | | | |
| | (a) Basic (In ₹) | 10.37 | 13.15 | 14.00 | 35.33 | 37.30 | 46.58 |
| | (b) Diluted (In ₹) | 10.37 | 13.15 | 14.00 | 35.33 | 37.30 | 46.58 |

Notes:

- The above standalone un-audited financial results of the Company for the quarter and nine months ended on December 31, 2024 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 13, 2025. The auditor have carried out an limited review of the said financial results.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: February 13, 2025

SAMIR M. SHAH & ASSOCIATES

Chartered Accountants

"Heaven", 8, Western Park Society, Nr. Inducto therm,
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

Limited Review Report on standalone un-audited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To
The Board of Directors of,
Lincoln Pharmaceuticals Limited,
Ahmedabad

1. We have reviewed the accompanying statement of unaudited standalone financial results of **Lincoln Pharmaceuticals Limited** ("the Company") having its Registered Office at "LINCOLN HOUSE", Behind Satyam Complex, Science City Road, Sola, Ahmedabad – 380060, Gujarat for the quarter ended December 31, 2024 and for the year to date period from April 01, 2024 to December 31, 2024 ("the statement"). This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad

Date: 13/02/2025



For, Samir M Shah & Associates

Chartered Accountants,

[Firm Regd. No. 122377W]

(Samir M Shah)

Partner

[M. No. 111052]

[UDIN: 25111052BMJWRZ2324]

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad-380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-4107-8000,

Website: www.lincolnpharma.com, E-Mail: investor@lincolnpharma.com

Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine Months Ended on 31-December-2024.

| Sr. No. | Particulars | ₹ in Lakhs Except Earnings Per Share Data | | | | | |
|---------|--|---|----------------------------|----------------------------|----------------------------|----------------------------|-------------------------|
| | | Quarter Ended | | | Nine Months Ended | | Year Ended |
| | | 31/12/2024 (Un-Audited) | 30/09/2024 (Un-Audited) | 31/12/2023 (Un-Audited) | 31/12/2024 (Un-Audited) | 31/12/2023 (Un-Audited) | 31/03/2024 (Audited) |
| 1 | Income | | | | | | |
| | A) Revenue From Operations | 14,655.17 | 16,121.35 | 14,644.93 | 45,504.70 | 43,805.66 | 58,054.96 |
| | B) Other Income | 897.00 | 997.76 | 1,101.79 | 2,935.68 | 2,740.34 | 3,442.25 |
| | Total Income (1) | 15,552.17 | 17,119.11 | 15,746.72 | 48,440.38 | 46,546.00 | 61,497.21 |
| 2 | Expenses | | | | | | |
| | A) Cost of Material Consumed | 5,015.90 | 5,710.33 | 5,687.75 | 16,000.79 | 14,923.73 | 20,112.45 |
| | B) Purchase of Stock-In-Trade | 1,860.91 | 2,185.50 | 3,051.04 | 5,379.48 | 6,591.31 | 8,291.48 |
| | C) Changes In Inventories of Finished Goods, Stock-In-Trade and WIP | (13.25) | (666.49) | (2,029.79) | (263.51) | (1,038.89) | (570.06) |
| | D) Employee Benefits Expenses | 2,797.78 | 2,783.62 | 2,643.68 | 8,483.39 | 7,784.70 | 10,289.96 |
| | E) Finance Costs | 72.81 | 34.88 | 15.47 | 151.60 | 96.57 | 146.49 |
| | F) Deprecation and Amortisation Expense | 322.43 | 322.44 | 281.38 | 967.30 | 793.89 | 1,062.47 |
| | G) Other Expenses | 2,627.49 | 3,270.51 | 2,326.15 | 8,427.12 | 7,392.14 | 9,940.16 |
| | Total Expenses (2) | 12,684.07 | 13,640.79 | 11,975.68 | 39,146.17 | 36,543.45 | 49,272.95 |
| 3 | Profit / (Loss) Before Exceptional Items & Tax (1-2) | 2,868.10 | 3,478.32 | 3,771.04 | 9,294.21 | 10,002.55 | 12,224.26 |
| 4 | Exceptional Items | Nil | Nil | Nil | Nil | Nil | Nil |
| 5 | Profit / (Loss) after Exceptional items but Before Tax (3-4) | 2,868.10 | 3,478.32 | 3,771.04 | 9,294.21 | 10,002.55 | 12,224.26 |
| 6 | Tax Expense | | | | | | |
| | A) Current Tax | 754.90 | 511.80 | 721.00 | 1,818.00 | 2,133.00 | 2,520.50 |
| | B) Deferred Tax | (13.34) | 333.49 | 246.01 | 349.47 | 398.76 | 349.48 |
| | C) Short / (Excess) Tax Provision | 49.60 | Nil | Nil | 49.60 | Nil | 23.79 |
| 7 | Net Profit / (Loss) For The Period (5-6) | 2,076.94 | 2,633.03 | 2,804.03 | 7,077.14 | 7,470.79 | 9,330.49 |
| 8 | Attributable to Non-Controlling Interest | Nil | Nil | Nil | Nil | Nil | Nil |
| | Attributable to Owners of the Company | 2,076.94 | 2,633.03 | 2,804.03 | 7,077.14 | 7,470.79 | 9,330.49 |
| 9 | Other Comprehensive Income (Net Of Tax) | | | | | | |
| | Items that will not be reclassified to subsequently to profit and loss | 1.52 | 1.53 | (7.44) | 4.58 | (22.33) | 6.11 |
| | Items that will be reclassified subsequently to profit or loss | Nil | Nil | Nil | Nil | Nil | Nil |
| 10 | Total Comprehensive Income | 2,078.46 | 2,634.56 | 2,796.59 | 7,081.72 | 7,448.46 | 9,336.60 |
| 11 | Paid-Up Equity Share Capital (Face Value Of Rs. 10/- Each) | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 | 2,002.97 |
| 12 | Other Equity | | | | | | 57,280.62 |
| 13 | Earnings Per Share (of Rs. 10/- Each) (Not Annualised) | | | | | | |
| | (a) Basic (In ₹) | 10.37 | 13.15 | 14.00 | 35.33 | 37.30 | 46.58 |
| | (b) Diluted (In ₹) | 10.37 | 13.15 | 14.00 | 35.33 | 37.30 | 46.58 |

Notes:

- The above consolidated un-audited financial results of the Company for the quarter and nine months ended on December 31, 2024 have been reviewed and recommended by the audit committee and approved by the board of directors of the Company in their meeting held on Thursday, February 13, 2025. The auditor have carried out an limited review of the said financial results.
- This financial statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
- The Company has a single business segment namely 'Pharmaceutical Business'.
- The figures for the previous period / year have been regrouped / reclassified, wherever necessary to conform to current period / year classification.
- Consolidated un-audited financial results includes results of one subsidiary namely Zullinc Healthcare LLP.

For Lincoln Pharmaceuticals Limited



Mahendra G. Patel

Mahendra G. Patel
Managing Director
DIN: 00104706

Place: Ahmedabad
Date: February 13, 2025

SAMIR M. SHAH & ASSOCIATES

Chartered Accountants

"Heaven", 8, Western Park Society, Nr. Inductotherm,
Bopal, Ahmedabad – 380058

Phone : +91- 76220 12032

E-mail : samir@smshah.co.in

Limited Review Report on consolidated unaudited quarterly and year to date financial results of Lincoln Pharmaceuticals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

To

The Board of Directors of,

Lincoln Pharmaceuticals Limited,

Ahmedabad

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **Lincoln Pharmaceuticals Limited**("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended December 31, 2024 and for the year to date period from April 01, 2024 to December 31, 2024("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended(the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities:

- | | | |
|------------------------------------|---|-------------------------|
| A. Lincoln Pharmaceuticals Limited | - | Parent Company |
| B. Zullinc Healthcare LLP | - | Wholly-Owned Subsidiary |

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of one subsidiary included in the consolidated unaudited financial results, whose interim financial information reflects total income of Rs.Nil Lakhs, total net loss of Rs.0.01 Lakhs for the nine months ended December 31, 2024, as considered in the statement. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, are based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the statement in respect of matters stated in para 6 above is not modified.

Place: Ahmedabad
Date: 13/02/2025



For, Samir M Shah & Associates
Chartered Accountants,

[Firm Regd. No. 122377W]

(Samir M Shah)

Partner

[M. No. 111052]

[UDIN:25111052BMJWSA6545]

Media Release

Lincoln Pharmaceuticals Ltd reports Standalone Net Profit of Rs. 20.77 crore in Q3 FY25

- Revenue from Operations to Rs. 146.55 crore in Q3 FY25

Highlights:-

- For 9MFY25, Net Profit to Rs. 70.77 crore; EBITDA to Rs. 104.13 crore; Revenue from Operations to Rs. 455.05 crore
- Company achieved Profit Before Tax of Rs. 92.94 crores for 9M FY25 ended December 2024.
- FII's steadily raised holding in the company to 5.16% as of Dec 2024 from 3.22% as on Dec 2023.
- Company achieved milestone of Profit Growth Every Single Year from FY13 to FY24.
- Company is targeting revenue of Rs. 750 crore in FY26.

Ahmedabad (Gujarat), February 13, 2025: Lincoln Pharmaceuticals Limited, one of India's leading healthcare companies has reported a standalone net profit of Rs. 20.77 crore for the Q3 FY25 ended December 2024 as against net profit of Rs. 28.04 crore in the corresponding period last year. Revenue from operations for the Q3 FY25 was reported at Rs. 146.55 crore over previous fiscal's same period revenue from operations of Rs. 146.45 crore. Company reported EBITDA of Rs. 32.63 crore in Q3 FY25 as compared to Rs. 40.68 crore EBITDA in the corresponding period last year. EPS for Q3FY25 was at Rs. 10.37 per share.

The company reported a profit before tax of Rs. 92.94 crores for the nine months ended December 2024 (9M FY25) to Rs. 100.03 crores in 9M FY24. Foreign Institutional Investors (FIIs) have steadily increased their stake in the company, rising from 3.22% in December 2023 to 5.16% in December 2024. With a clear growth strategy, the company is targeting revenue of Rs. 750 crores by FY26, driven by business expansion into high-value product lines and entry into new markets. Notably, the company is among the select few to achieve consistent profit growth every year from FY13 to FY24.

Financial Highlights (Standalone)

(Amount in Cr except EPS)

| Particulars | Q3 FY25 | Q3 FY24 | Y-O-Y (%) | 9M FY25 | 9M FY24 | Y-O-Y (%) |
|-------------------------|---------|---------|-----------|---------|---------|-----------|
| Revenue from Operations | 146.55 | 146.45 | 0.07% | 455.05 | 438.06 | 3.88% |
| EBITDA | 32.63 | 40.68 | -19.79% | 104.13 | 108.93 | -4.41% |
| Profit before Tax | 28.68 | 37.71 | -23.95% | 92.94 | 100.03 | -7.09% |
| Net Profit | 20.77 | 28.04 | -25.93% | 70.77 | 74.71 | -5.27% |
| E.P.S (Rs.) | 10.37 | 14.00 | -25.93% | 35.33 | 37.30 | -5.28% |

Commenting on the results and performance, **Mr. Mahendra Patel, Managing Director, Lincoln Pharmaceuticals Limited**, said, "We are pleased to report strong growth across all business verticals in the first nine months of FY25, with a vision to achieve record revenue, EBITDA, and net profit for the full year. Company aims to maintain a steady grow while maintaining a net debt-free status. Our new product launches in domestic and export markets have boosted growth and market presence. Driven by strategic initiatives, operational excellence, and geographic expansion, we are on track to achieve Rs. 750 crore revenue target by FY26. Notably, we are among the few companies with consistent profit growth from FY13 to FY24."

Highlights: - 9M FY25 Results

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | Fax : +91-79-4107 8062 | CIN L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | Website : www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, (Guj.) | Phone : +91-79-49135000 | E-mail : khatraj@lincolnpharma.com



For nine months ended December 2024, company reported a standalone revenue from operations of Rs. 455.05 crore over previous fiscal's same period revenue from operations of Rs. 438.06 crore. Net profit of the company was reported at Rs. 70.77 crore for the nine months ended December 2024 as against net profit of Rs. 74.71 crore in the corresponding period last year. EBITDA for the 9M FY25 ended December 2024 was reported at Rs. 104.13 crore as compared to EBITDA of Rs. 108.93 crore in 9M FY24. EPS for the nine months of FY25 was reported at Rs. 35.33 per share. Exports (FOB) in nine months of FY25 was reported at Rs. 271.83 crore.

The company's growth strategy focuses on expanding its global footprint by registering new products for export, enhancing market presence, and utilizing state-of-the-art manufacturing facilities that meet international standards. With a strong foundation in the acute segment, the company is now building a robust portfolio in lifestyle and chronic segments, particularly in women's healthcare and dermatology. Supported by healthy cash accruals, no-term debt, and strong return ratios, the company's liquidity remains solid. Committed to R&D and innovation, it boasts a portfolio of over 1,700 registered products and 700 more in development.

Currently exporting to 60+ countries across East and West Africa, Central and North America, Latin America, and Southeast Asia, the company recently entered the Canadian market and secured approvals from TGA - Australia and EU GMP. These milestones, along with product registration for its Cephalosporin plant in Mehsana, are key drivers of its global expansion strategy to over 90 plus countries. Aligned with these efforts, the company remains on track to achieve its ambitious Rs. 750 crore revenue target by FY26.

Company has a state-of-the-art manufacturing facility unit at Khatraj in Ahmedabad, Gujarat, complying with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has filed 25 plus patent applications and is awarded with seven patents.



Lincoln Pharmaceuticals Limited: <https://www.lincolnpharma.com/>

Providing Affordable and Innovative medicines for healthier lives.

Lincoln Pharmaceuticals Limited is one of the leading healthcare companies in Gujarat, India. Established in the year 1979, the company develops and manufactures affordable and innovative medicines for healthier lives. The company has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio & CNS, anti-bacterial, anti-diabetic, anti-malaria among others. Company has over 1,700 registered products and another 700 in pipeline. The company has its strong presence in Domestic market with good strength of own field force and also exports to more than 60 Countries.

Company has developed many new drug delivery dosage forms over years and has a track record of launching many first-of-its-kind innovative products. Company works with vision for nurturing innovations and bringing them to Indian patients at affordable cost to create **“Healthcare for All”**.

Lincoln Pharma has two state-of-the-art manufacturing facility units at Khatraj in Ahmedabad and Mehsana, Gujarat. Company’s manufacturing facilities comply with stringent international quality and compliance norms and certified by EUGMP, TGA, WHO-GMP; ISO-9001:2015, ISO-14001:2015 and ISO-45001:2018. Company is engaged in manufacturing of pharma formulations like Tablets, Capsules, Injectables, Syrups, Ointments, etc.

Company's key strength is embedded in its cutting-edge research and development capabilities. The company has a strong R&D team including 30 plus scientists. It has filled 25 plus patent applications and is awarded seven patents. R&D facility of the company is recognised by the Department of Scientific and Technology, Government of India and furnished with state-of-the-art devices and equipment for internal physical, chemical and microbiological analysis of all products.

Company has a strong presence in the domestic market nationally with a dedicated field force of over 600. Company has a wide national distribution network through 21+ Super Stockist in 26 states across India.

Going green, company has also set up a new Solar Plant of 1 MW at factory’s rooftop in addition to two windmills. This way we are producing renewable energy to our consumption nearly 65% resulting significant saving in the electricity cost and helped the company to become a self-sustainable and environment-friendly organization.

For further information please contact:

Gopal Modi
DSNN Consultancy
9099030184
gopal@dsnnconsultancy.com



Darshit A. Shah (CFO)
Lincoln Pharmaceuticals Ltd
+91-79-4107-8048
darshit@lincolnpharma.com

QUARTERLY INTEGRATED FILING (FINANCIAL)

In compliance of Circular No SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31st December 2024, on quarterly integrated filing (Financial):

- A. FINANCIAL RESULTS.- Annexed above.**
- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC. - Not Applicable.**
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES- Not Applicable.**
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) - Not Applicable.**
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) - Not Applicable.**

Regd. Office : "Lincoln House", B/h. Satyam Complex, Science City Road, Sola, Ahmedabad-380060, Gujarat, India.

Phone : +91-79-4107 8000 | **CIN** L24230GJ1995PLC024288

E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : Trimul Estate, Khatraj, Tal.- Kalol, Dist.- Gandhinagar-382721, Gujarat State, India

Phone : +91-79-4913 5000 | **E-mail :** khatraj@lincolnpharma.com

